Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-exploration study of continuous subcutaneous infusion of beinaglutide in overweight or obese adults
CTR20263346Phase 2Active
- Sponsor
- RemeGen
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of beinaglutide in obesity, Overweight, sponsored by RemeGen. Started Sep 2026; status: active.
02
Drugs
beinaglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20263346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263346.